These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35958877)

  • 1. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
    Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
    J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
    Fang F; Lu J; Sang X; Tao YF; Wang JW; Zhang ZM; Zhang YP; Li XL; Xie Y; Wu SY; Chu XR; Li G; Wu D; Chen YL; Yu JJ; Jia SQ; Feng CX; Tian YY; Li ZH; Ling J; Hu SY; Pan J
    J Exp Clin Cancer Res; 2022 Jul; 41(1):225. PubMed ID: 35842703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes.
    Yu J; Yang Y; Zhou R; Tao Y; Zhu F; Jiao W; Zhang Z; Ji T; Li T; Fang F; Xie Y; Wu D; Zhuo R; Li X; Chen Y; Yin H; Wang J; Pan J
    Carcinogenesis; 2024 Jun; 45(6):424-435. PubMed ID: 38302114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
    Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
    Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma.
    Wu D; Yin H; Yang C; Zhang Z; Fang F; Wang J; Li X; Xie Y; Hu X; Zhuo R; Chen Y; Yu J; Li T; Li G; Pan J
    BMC Cancer; 2024 Aug; 24(1):928. PubMed ID: 39090568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
    Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
    Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
    Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m
    Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
    Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
    Zhang K; Gao L; Wang J; Chu X; Zhang Z; Zhang Y; Fang F; Tao Y; Li X; Tian Y; Li Z; Sang X; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Hu S
    Pathol Oncol Res; 2022; 28():1610447. PubMed ID: 35832114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
    Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
    Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
    Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
    Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
    [No Abstract]   [Full Text] [Related]  

  • 14. Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.
    Baragaño Raneros A; Rodriguez RM; Bernardo Flórez A; Palomo P; Colado E; Minguela A; Suárez Álvarez B; López-Larrea C
    Oncoimmunology; 2021 Mar; 10(1):1897294. PubMed ID: 33796404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
    Bauer K; Hauswirth A; Gleixner KV; Greiner G; Thaler J; Bettelheim P; Filik Y; Koller E; Hoermann G; Staber PB; Sperr WR; Keil F; Valent P
    Am J Hematol; 2024 Sep; 99(9):1721-1731. PubMed ID: 38822666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.
    Shen C; Ipsaro JJ; Shi J; Milazzo JP; Wang E; Roe JS; Suzuki Y; Pappin DJ; Joshua-Tor L; Vakoc CR
    Mol Cell; 2015 Dec; 60(6):847-59. PubMed ID: 26626481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
    Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
    Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.